Japan Precision Medicine Market Size & Outlook, 2026-2033
The precision medicine market in Japan is expected to reach a projected revenue of US$ 39,804.2 million by 2033. A compound annual growth rate of 23.4% is expected of Japan precision medicine market from 2026 to 2033.
The Japan precision medicine market generated a revenue of USD 7,462.9 million in 2025 and is expected to reach USD 39,804.2 million by 2033.
The Japan market is expected to grow at a CAGR of 23.4% from 2026 to 2033.
In terms of segment, therapeutics was the largest revenue generating application in 2025.
Diagnostics is the most lucrative application segment registering the fastest growth during the forecast period.
Precision medicine market data book summary
Market revenue in 2025
USD 7,462.9 million
Market revenue in 2033
USD 39,804.2 million
Growth rate
23.4% (CAGR from 2026 to 2033)
Largest segment
Therapeutics
Fastest growing segment
Diagnostics
Historical data
2021 - 2024
Base year
2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Diagnostics, Therapeutics
Key market players worldwide
Roche, Siemens Healthineers AG ADR, Janssen Pharmaceuticals, Illumina Inc, Quest Diagnostics Inc, 23andMe Holding Co Class A, NeoDiagnostix, International Business Machines Corp, Myriad Genetics Inc, Medtronic PLC, GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Dakota Software, Biogen Inc, Qiagen NV, ImmunityBio Inc Ordinary Shares
Other key industry trends
In terms of revenue, Japan accounted for 6.4% of the global precision medicine market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Asia Pacific, Japan precision medicine market is projected to lead the regional market in terms of revenue in 2033.
Japan is the fastest growing regional market in Asia Pacific and is projected to reach USD 39,804.2 million by 2033.
In Japan, the government has established an Integrated Community Care System that seamlessly combines healthcare, long-term care, housing, and livelihood support services. This system allows the elderly to receive continuous, high-quality care within their local communities rather than in hospitals, reducing healthcare costs & hospital use and improving health outcomes.
Despite challenges, such as the low percentage of cancer patients receiving personalized drugs based on genomic profiling, R&D is expanding. Japan’s collaboration with other Asian countries under the SCRUM-Japan project, led by the National Cancer Center Hospital East, exemplifies this growth.
In September 2022, the Japanese government approved the "Whole Genome Analysis 2022" Action Plan to integrate personalized medicine into routine medical care, with progress being made in addressing related issues. Since the approval of cancer genetic testing in 2019, Japan has been advancing the social implementation of personalized medicine.
Japan precision medicine diagnostics therapeutics market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Precision Medicine Market Outlook will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 89.67% in 2025.
Horizon Databook has segmented the Japan precision medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2021 to 2033.
In Japan, the government has established an Integrated Community Care System that seamlessly combines healthcare, long-term care, housing, and livelihood support services. This system allows the elderly to receive continuous, high-quality care within their local communities rather than in hospitals, reducing healthcare costs & hospital use and improving health outcomes.
Despite challenges, such as the low percentage of cancer patients receiving personalized drugs based on genomic profiling, R&D is expanding. Japan’s collaboration with other Asian countries under the SCRUM-Japan project, led by the National Cancer Center Hospital East, exemplifies this growth.
In September 2022, the Japanese government approved the "Whole Genome Analysis 2022" Action Plan to integrate personalized medicine into routine medical care, with progress being made in addressing related issues. Since the approval of cancer genetic testing in 2019, Japan has been advancing the social implementation of personalized medicine.
Japan Precision Medicine Market Application Outlook (Revenue, USD Million , 2021-2033)
Diagnostics
Therapeutics
Japan Precision Medicine Market End Use Outlook (Revenue, USD Million , 2021-2033)
Home Care
Hospitals
Clinical Laboratories
Others
Reasons to subscribe to precision medicine diagnostics therapeutics market databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of precision medicine diagnostics therapeutics market databook
Our clientele includes a mix of precision medicine diagnostics therapeutics market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan precision medicine diagnostics therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Japan precision medicine diagnostics therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.